Search Results

Pfizer's LORBRENA sNDA in previously untreated ALK-positive lung cancer accepted for priority review by U.S. FDA

LORBRENA is a third-generation ALK inhibitor specifically developed to inhibit the most common tumour mutations that drive resistance to current medications and to address ...
Dec 29